A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

NCT02694770 | Withdrawn Phase 2 DMC

• 1 other identifier: 2015.011.01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 2

Brief Summary

This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease

Conditions

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation

Keywords

aGvHD; GvHD; sr-aGvHD; biologics; monoclonal antibody

Outcome Measures

Primary Outcomes (1)

• Overall response rate (Complete Response+Partial Response)

  Day 28 after the initiation of sr-aGvHD treatment

Secondary Outcomes (6)

• Overall response rate (Complete Response+Partial Response)

  Day 56 after the initiation of sr-aGvHD treatment

• Complete Response+Very Good Partial Response

  Day 28 and Day 56 after the initiation of sr-aGvHD treatment

• Overall survival

  Day 180 after the initiation of sr-aGvHD treatment

• Cumulative steroid dose

  Day 28 after the initiation of sr-aGvHD treatment

• Cumulative incidence of chronic GvHD

  Day 180 after the initiation of sr-aGvHD treatment

Study Arms (2)

Neihulizumab

EXPERIMENTAL

Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.

Biological: Neihulizumab Treatment

"Conventional Treatment"

ACTIVE COMPARATOR

Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.

Biological: Conventional Treatment

Interventions

Neihulizumab Treatment BIOLOGICAL

Monoclonal antibody

Also known as: AbGn-168H

Neihulizumab

Conventional Treatment BIOLOGICAL

2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.

"Conventional Treatment"

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must be ≥18years of age, males or females;
• Patient must have been recipients of a single allogeneic HCT; bone marrow, peripheral blood and/or umbilical cord blood recipients are allowed
• Patients must have aGvHD without feature of classic chronic GvHD or overlap GvHD;
• Patients must have received no prior treatment for aGvHD other than steroids;
• Patients must have biopsy proven grade II to IV aGvHD progressing after at least 3 days, non-improving grade III to IV aGvHD persistent after at least 7 days, or non-improving grade II aGvHD persistent after at least 14 days of methylprednisolone 2mg/kg/day or equivalent; Patients with initial response but have flare of aGvHD within 14 days with methylprednisolone \> 0.5 mg/kg/day or equivalent are also eligible;
• Patient must have an ANC of \> 500/mm3 and no evidence of HCT graft failure or multi-organ failure;
• Patient must have Karnofsky Performance Status (KPS) ≥50%;
• Patient must give informed consent and sign an approved consent form prior to any study procedures;
• Females of childbearing potential must have a negative pregnancy test result prior to enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study.

You may not qualify if:

• Uncontrolled infections not responsive to antimicrobial therapy or requiring intensive critical care or vasopressors;
• Evidence of end-organ infection due to CMV;
• HIV infection or a known HIV-related malignancy (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case by case basis).
• Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis
• Donor lymphocyte infusion for residual or relapsed disease or mixed chimerism. DLI as part of the planned HCT protocol are allowed
• Relapsed disease after transplant or progressive malignant disease, including post-transplant lymphoproliferative disease; any secondary malignancy diagnosed since HCT
• Renal failure requiring hemodialysis
• Need ICU care, with life expectancy of less than 28 days, with ongoing or unresolved veno-occlusive disease, with unstable hemodynamics, with evidence of current or previous clinically significant disease, medical condition or finding of the medical examination (including vital signs and ECG), that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data
• History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
• Pregnant or nursing

Sponsors & Collaborators

• AbGenomics B.V Taiwan Branch: lead

Study Sites (2)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States

Location

Study Officials

• Shih-Yao Lin, MD, PhD

  AbGenomics B.V.

  STUDY CHAIR

• Paul Martin (Lead), MD

  Fred Hutchinson Cancer Center

  PRINCIPAL INVESTIGATOR

• Marco Mielcarek (Co-Lead), MD

  Fred Hutchinson Cancer Center

  PRINCIPAL INVESTIGATOR

• Amin Alousi (Co-Lead), MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2016
• First Posted: March 1, 2016
• Study Start: July 1, 2016
• Primary Completion: September 1, 2017
• Study Completion: February 1, 2018
• Last Updated: April 25, 2016

Record last verified: 2016-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)